Pelotonia Institute for Immuno-Oncology/X
Apr 13, 2025, 14:44
First-in-Human PIIO-1 Trial for Recurrent Glioblastoma Receives IND Approval – Pelotonia Institute for Immuno-Oncology
Pelotonia Institute for Immuno-Oncology shared a post on X:
“We’re celebrating IND approval for the first in human PIIO-1 trial — a groundbreaking CAR-T Cell Therapy for recurrent glioblastoma!
This novel approach targets GARP and delivers engineered T cells directly into the tumor.
A major milestone for GBM research and immunotherapy!”
More posts featuring Pelotonia Institute for Immuno-Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 4, 2025, 14:43
Aug 4, 2025, 14:39
Aug 4, 2025, 14:38
Aug 4, 2025, 14:30
Aug 4, 2025, 13:47
Aug 4, 2025, 13:24
Aug 4, 2025, 13:01
Aug 4, 2025, 12:30
Aug 4, 2025, 12:06